Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002895769 | SCV003249598 | uncertain significance | Hereditary spastic paraplegia 64 | 2022-06-30 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs146324431, gnomAD 0.02%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with ENTPD1-related conditions. This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 87 of the ENTPD1 protein (p.Lys87Glu). |
Ambry Genetics | RCV004066099 | SCV004863049 | uncertain significance | Inborn genetic diseases | 2024-02-26 | criteria provided, single submitter | clinical testing | The c.295A>G (p.K99E) alteration is located in exon 3 (coding exon 3) of the ENTPD1 gene. This alteration results from a A to G substitution at nucleotide position 295, causing the lysine (K) at amino acid position 99 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |